MIR490: MIR490 is a methylated miRNA that has been found in both cell lines and control B cells, as shown by methylation specific PCR (MSP) [PMC5485978]. It is also present in extracellular vesicles (EVs) derived from human periodontal ligament stem cells (hPDLSCs) [PMC7287171]. MIR490, along with MIR335 and MIR296, targets less than 200 genes each [PMC7287171]. In bladder cancer cells, MIR490 acts as a suppressor of cell proliferation by blocking the transcription of FOS [PMC7287171]. It has also been found to inhibit the expression of HMGA2 in osteosarcoma and affect the development potential of the cancer [PMC7287171]. In lung cancer cells A549 and ovarian cancer, MIR490 blocks the transcription of CCND1 and CDK1 respectively, both important genes involved in cell cycle progression [PMC7287171]. The expression of MIR490 can be regulated by CCAT1 in gastric cancer, and its high expression can decrease the expression of CCAT1 and restrain metastasis [PMC9844612]. In multiple myeloma patients, high expression levels of miR153, MIR490, miR455, miR642, miR500, and miR296 are associated with favorable prognosis [PMC6183594]. In lung adenocarcinoma (LUAD), down-regulation of MIR490 is observed while up-regulation of MALAT1 and HMGA2 is observed. The ceRNA network involving MALAT1 as a competing endogenous RNA for MIR490 may contribute to tumor progression in LUAD [PMC7212445]. Overall survival outcomes are poorer in lung cancer patients with lower expression levels of MIR490. Gain- and loss-of-function studies have shown that overexpression of MIR490 reduces proliferation, promotes G1 arrest and apoptosis, and suppresses migration and invasion [PMC7212445].